Clinical Trial Update: ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension [Phase 3]

View source ↗

Summary

Phase 3 trial MNKD-101 (Clofazimine inhalation suspension) for MAC lung disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacterium Avium Complex Lung Disease
• Nontuberculous Mycobacterial Infections

Drugs mentioned

• MNKD-101 (Clofazimine inhalation suspension)

Snippet

Sponsor: Mannkind Corporation | Conditions: MAC Lung Disease, Treatment Refractory MAC Lung Disease | Phase 3 | Status: TERMINATED